Source-grounded facts extracted from ALX ONCOLOGY HOLDINGS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ALX ONCOLOGY HOLDINGS INC reported financial results for the first quarter ended March 31, 2026.
“On May 8, 2026, ALX Oncology Holdings Inc. (the “Company”), issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
ALX ONCOLOGY HOLDINGS INC entered into Underwriting Agreement with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives of the several underwriters valued at approximately $150 million (effective 2026-01-30).
“On January 30, 2026, ALX Oncology Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co., UBS Securities LLC and Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several underwriters named therein (collectively, the “Underwriters”), relating to the issuance and sale (the “Offering”) of 76,979,112 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at an offering price of $1.57 per share and pre-funded warrants (the “Pre-Funded Warrants”) to purchase 18,574,120 shares of Common Stock at an offering price of $1.569 per Pre-Funded Warrant.”
Jaume Pons departed as President and Chief Scientific Officer at ALX ONCOLOGY HOLDINGS INC.
“the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025”
Chris Takimoto was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board”
Barbara Klencke was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board”
Shelly Pinto resigned as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.”
Harish Shantharam was appointed as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer”
Alan Sandler resigned as member of the Board at ALX ONCOLOGY HOLDINGS INC.
“Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.”
Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.”
Alan Sandler was appointed as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.”
Shelly Pinto was appointed as Interim Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.”
Peter Garcia resigned as Chief Financial Officer at ALX ONCOLOGY HOLDINGS INC.
“On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.”
Sophia Randolph resigned as Chief Medical Officer at ALX ONCOLOGY HOLDINGS INC.
“On September 30, 2024, Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology Holdings Inc. (the “Company”) informed the Company of her resignation from her position effective October 11, 2024, to pursue other professional opportunities.”
Sophia Randolph resigned as Director at ALX ONCOLOGY HOLDINGS INC.
“In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.”
Jaume Pons resigned as Director at ALX ONCOLOGY HOLDINGS INC.
“In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.”
Alan Sandler was appointed as Director at ALX ONCOLOGY HOLDINGS INC.
“On August 5, 2024, the Board of Directors of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D. to serve as a Class III director of the Board of Directors of the Company (the “Board”) for a term expiring at the 2026 annual meeting of stockholders”
ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2024.
“On May 9, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Itziar Canamasas resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.
“On April 30, 2024, Itziar Canamasas, Ph.D., informed the Company of her resignation as a member of the Board and all committees thereof, effective immediately, due to her taking a new professional position that does not permit her to continue on as a director of the Company.”
Jack Nielsen resigned as member of the Board of Directors at ALX ONCOLOGY HOLDINGS INC.
“On April 28, 2024, Jack Nielsen informed ALX Oncology Holdings Inc. (the “Company”) of his resignation as a member of the Company’s Board of Directors (the “Board”) and all committees thereof, effective immediately, due to health reasons.”
ALX ONCOLOGY HOLDINGS INC reported the fourth quarter and full year ended December 31, 2023 results: net income GAAP net loss was $45.5 million for the fourth quarter ended December 31, 2023, or ($0.93) per basic and diluted share, EPS ($0.93) per basic and diluted share.
“On March 7, 2024, ALX Oncology Holdings Inc. (the "Company"), issued a press release announcing its financial results for the fourth quarter and full year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.